Kim Kelderman is recorded as Board Member at BIO-TECHNE Corp (TECH) since February 1, 2024, COO at BIO-TECHNE Corp (TECH) since November 1, 2023 and CEO at BIO-TECHNE Corp (TECH). BIO-TECHNE Corp reported in an 8-K filed January 8, 2024 that Kim Kelderman was appointed Chief Executive Officer, effective February 1, 2024. BIO-TECHNE Corp reported in an 8-K filed October 19, 2023 that Kim Kelderman was appointed Director, effective February 1, 2024. BIO-TECHNE Corp reported in an 8-K filed October 19, 2023 that Kim Kelderman was appointed Chief Executive Officer, effective February 1, 2024. Equibles holds 4 filed executive changes naming Kim Kelderman; each is listed under recent activity with its source filing. The proxy statement of BIO-TECHNE Corp reports total compensation of $8,151,181 for Kim Kelderman in fiscal 2025, including a base salary of $936,000. Disclosed compensation is on record for 7 fiscal years. Kim Kelderman has spoken on 11 earnings calls and 1 other investor event across 1 company, most recently for BIO-TECHNE Corp on May 12, 2026. BIO-TECHNE Corp is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BIO-TECHNE Corp includes Charles Kummeth (CEO), James T. Hippel (CFO), Shane Bohnen (General Counsel) and 7 others.
“Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024.”
BIO-TECHNE Corp Form 8-K, filed January 8, 2024
· Read the filing
“Also effective February 1, 2024, Mr. Kelderman will be appointed Chief Executive Officer and Director.”
BIO-TECHNE Corp Form 8-K, filed October 19, 2023
· Read the filing
Kim Kelderman on recent calls
“I mean, maybe just to kick things off, you recently reported um any highlights from the quarter you'd like to talk through sort of how it played out relative to expectations you know what was a little bit better what was a little bit worse yeah um so yeah we reported our q3 um and uh printed negative two percent…”
“The biotechnic team continued to execute with discipline in a dynamic and uneven end market environment. Our quarterly performance was supported by sustained strength from our large pharmaceutical customers and stable to improving trends in our U.S. academic end market.”
“Our second quarter performance was largely in line with our expectations. Continued strength from our large farmer customers was offset by a soft, yet improving biotech end market and a soft but stable U.S. academic end market.”
“I'm pleased to report that we delivered a solid quarter that was in line with our expectations. The team's continued execution drove 3% organic revenue growth in a dynamic operating environment.”
